MERZ-AESTHETICS
Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 20th Aesthetic & Anti-Aging Medicine World Congress (AMWC), with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diverse society. AMWC 2022, held from Thursday, 31 March to Saturday, 02 April 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Monaco and/or virtually. Merz Aesthetics is an elite sponsor of the global industry congress.
“As part of our continued commitment to the aesthetic medicine industry, we are looking forward to reunite with partners and experts, share insights and foster scientific exchange in the aesthetics field at this year’s AMWC congress,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We are focused to advance science in aesthetics, fuel confidence and empower unique attitudes.”
Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs – by fueling confidence and empowering unique attitudes.
Merz Aesthetics is organizing an expert program led by esteemed medical aesthetic experts and presenting new data throughout the course of the meeting.
Expert Keynote Sessions
Merz Aesthetics is organizing expert-led keynote sessions to be held on Thursday, 31 March – Friday, 01 April (via registration only).
- “Skin Glow and Skin Quality – optimizing your skin boosting treatment” – Dr. Sonja Sattler, Thursday, 31 March, 10:00-12:00h CEST.
- “Collagen Expert Class – insights into collagen stimulation, skin quality and patient safety” – Dr. Jani van Loghem, Thursday, 31 March, 13:00-15:00h CEST.
- “Optimizing the Patient Journey in the Digital Age” – Adam Haroun, Thursday, 31 March, 15:30-17:00h CEST.
- “Aesthetic Toxin Expert Talk – purity and precision for long-term patient satisfaction” – Dr. Carla Pecora, Friday 01 April, 10:00-12:00h CEST.
- “Skin Lifting – the expert approach to customized treatments” – Dr. Tatjana Pavicic, Friday 01 April, 13:00-15:00h CEST.
- “All About Lips – expert techniques to address the unique needs of patients” – Dr. Kate Goldie, Friday 01 April, 15:30 – 17:30h CEST
Oral Presentations
Dr. Carla Pecora: ‘Clinical experience with intradermal microdroplet injection of diluted Incobotulinum toxin A for facial flushing and pore size improvement’ (Neuromodulators); Saturday, 02 April, 9:00h CEST, Nijinski
Dr. Carla Pecora: ‘A combination approach using IncobotulinumtoxinA and CPM-HA injections for the periorbital complex improvement.’ (Periorbital Zone and “Foxy Eyes” Trend – Lifting & Rejuvenating); Saturday, 02 April, 11:15h CEST, Salle des Princes & AMWC Stream 1
E-Poster Presentations
Virtual posters will be available for viewing for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.
Botulinum Toxin
- Study Design of LONG RUN: A LONGitudinal evaluation and Real-world evidence of Uniquely purified incobotulinumtoxinA in treatment naïve participants. Andy Curry, Merz Aesthetics - USA, Terrence Keaney, MD – USA, Niamh Corduff, MD – Australia, Simon Ravichandran, MD – UK, Ada Trindade, MD – Brasil.
- Chemobioresurfacing: Does intradermal injection of botulinumtoxinA plus hyaluronic acid improve skin quality? Diane Duncan, MD – USA.
- IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.
Belotero® and Radiesse®
- The local tissue lifting capacity of dermal filler is greater with increasing hyaluronic acid concentration using an ex vivo human skin model. Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Thomas Hengl – all Merz Aesthetics, Germany.
- Distance between calcium hydroxylapatite microspheres is essential for fibroblast invasion and resulting neocollagenesis. Bartosch Nowag, Nils Warfving, Thomas Hengl – all Merz Aesthetics, Germany.
- Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Yana Yutskovskaya, MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com .
Copyright © 2022 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
